Cited by 145Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors

Open access

Dongiovanni, Paola·2014·World Journal of Gastroenterology

DOI 10.3748/wjg.v20.i36.12945PMC PMC4177475

Open this paper in CoChat — free account Open PDF

Abstract

Hepatocellular carcinoma (HCC) is the fourth cause of cancer related mortality, and its incidence is rapidly increasing. Viral hepatitis, alcohol abuse, and exposure to hepatotoxins are major risk factors, but nonalcoholic fatty liver disease (NAFLD) associated with obesity, insulin resistance, and type 2 diabetes, is an increasingly recognized trigger, especially in developed countries. Older age, severity of insulin resistance and diabetes, and iron overload have been reported to predispose to HCC in this context. Remarkably, HCCs have been reported in non-cirrhotic livers in a higher proportion of cases in NAFLD patients than in other etiologies. Inherited factors have also been implicated to explain the different individual susceptibility to develop HCC, and their role seems magnified in fatty liver, where only a minority of affected subjects progresses to cancer. In particular, the common I148M variant of the PNPLA3 gene influencing hepatic lipid metabolism influences HCC risk independently of its effect on the progression of liver fibrosis. Recently, rare loss-of-function mutations in Apolipoprotein B resulting in very low density lipoproteins hepatic retention and in Telomerase reverse transcriptase influencing cellular senescence have also been linked to HCC in NAFLD. Indeed, hepatic stellate cells senescence has been suggested to bridge tissue aging with alterations of the intestinal microbiota in the pathogenesis of obesity-related HCC. A deeper understanding of the mechanisms mediating hepatic carcinogenesis during insulin resistance, and the identification of its genetic determinants will hopefully provide new diagnostic and therapeutic tools.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3748/wjg.v20.i36.12945

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Global cancer statistics
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941
Rising Incidence of Hepatocellular Carcinoma in the United States
El‐Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,865

Show all 124 references

Research works printed but not linked: 1

10.2353/amjpath.2010.090249 · DOI

Sorted by citations

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis
Xu, F., Liu, C., Zhou, D., & Zhang, L. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155415627681 · Cited by 773
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Marengo, A., Rosso, C., & Bugianesi, E. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-013832 · Cited by 757
The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis
Saponaro, C., Gaggini, M., Carli, F., & Gastaldelli, A. (2015) · Nutrients · doi:10.3390/nu7115475 · Cited by 558
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review
Desai, A., Sandhu, S., Lai, J., & Sandhu, D. S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i1.1 · Cited by 328
PNPLA3 gene in liver diseases
Trépo, E., Romeo, S., Zucman‐Rossi, J., & Nahon, P. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.011 · Cited by 299
Predictors of early and late hepatocellular carcinoma recurrence
Nevola, R., Ruocco, R., Criscuolo, L., Villani, A., Alfano, M., Beccia, D., Imbriani, S., Claar, E., Cozzolino, D., Sasso, F. C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i8.1243 · Cited by 300
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., Luca, L. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 257
Self-citation
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Febbraio, M. A., Reibe, S., Shalapour, S., Ooi, G., Watt, M. J., & Karin, M. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.012 · Cited by 250
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.11.010 · Cited by 216
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study
Krawczyk, M. J., Rau, M., Schattenberg, J. M., Bantel, H., Pathil, A., Demir, M., Kluwe, J., Boettler, T., Lammert, F., & Geier, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p067454 · Cited by 204
Hepatocellular carcinoma: A comprehensive review
Waller, L. P. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i26.2648 · Cited by 196
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
Marchisello, S., Pino, A. D., Scicali, R., Urbano, F., Piro, S., Purrello, F., & Rabuazzo, A. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081948 · Cited by 202
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
Cholankeril, G. T., Patel, R., Khurana, S., & Satapathy, S. K. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i11.533 · Cited by 185
Should we undertake surveillance for HCC in patients with NAFLD?
Younes, R., & Bugianesi, E. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.006 · Cited by 165
Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease
Mantovani, A., & Targher, G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.04.41 · Cited by 170
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: An open question
Streba, L. A. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i14.4103 · Cited by 168
miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
Dongiovanni, P., Meroni, M., Longo, M., Fargion, S. R., & Fracanzani, A. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123966 · Cited by 139
Self-citation
Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease
Pelusi, S., Baselli, G., Pietrelli, A., Dongiovanni, P., Donati, B., McCain, M. V., Meroni, M., Fracanzani, A. L., Romagnoli, R., Petta, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39998-2 · Cited by 125
Self-citation
Nutrition and Genetics in NAFLD: The Perfect Binomium
Meroni, M., Longo, M., Rustichelli, A., & Dongiovanni, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082986 · Cited by 125
Self-citation
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120
Genetics of nonalcoholic fatty liver disease
Dongiovanni, P., & Valenti, L. V. C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.018 · Cited by 118
Self-citation
Liver‐Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer
Newberry, E. P., Hall, Z., Xie, Y., Molitor, E. A., Bayguinov, P. O., Strout, G. W., Fitzpatrick, J. A. J., Brunt, E. M., Griffin, J. L., & Davidson, N. O. (2021) · Hepatology · doi:10.1002/hep.31771 · Cited by 111
Glyceraldehyde‐3‐phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase
Liu, S., Sun, Y., Jiang, M., Li, Y., Tian, Y., Xue, W., Ding, N., Sun, Y., Cheng, C., Li, J., et al. (2017) · Hepatology · doi:10.1002/hep.29202 · Cited by 100
Emerging role of aging in the progression of NAFLD to HCC
He, Y., Su, Y., Duan, C., Wang, S., He, W. G., Zhang, Y., An, X., & He, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101833 · Cited by 100
PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis
Falleti, E., Cussigh, A., Cmet, S., Fabris, C., & Toniutto, P. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.09.009 · Cited by 90
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
Massoud, O. I., & Charlton, M. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.014 · Cited by 88
Hepatocellular carcinoma and non-alcoholic fatty liver disease
Golabi, P., Rhea, L. P., Henry, L. L., & Younossi, Z. M. (2019) · Hepatology International · doi:10.1007/s12072-019-09995-8 · Cited by 73
Hepatic Macrophage as a Key Player in Fatty Liver Disease
Xu, L., Liu, W., Bai, F., Xu, Y., Liang, X., Ma, C., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708978 · Cited by 73
Telomeres, NAFLD and Chronic Liver Disease
Donati, B., & Valenti, L. V. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030383 · Cited by 69
Genetics Is of the Essence to Face NAFLD
Meroni, M., Longo, M., Tria, G., & Dongiovanni, P. (2021) · Biomedicines · doi:10.3390/biomedicines9101359 · Cited by 69
Self-citation
ApoE deficiency promotes non-alcoholic fatty liver disease in mice via impeding AMPK/mTOR mediated autophagy
Lu, W., Mei, J., Yang, J., Wu, Z., Liu, J., Miao, P., Chen, Y., Wen, Z., Zhao, Z., Kong, H., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117601 · Cited by 65
Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis
Wang, J., Qiu, K., Zhou, S., Gan, Y., Jiang, K., Wang, D., & Wang, H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2455539 · Cited by 59
Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Santos, A. P., Santos, A. C., Castro, C., Raposo, L., Pereira, S. S., Torres, I., Henrique, R., Cardoso, H., & Monteiro, M. P. (2018) · Cancers · doi:10.3390/cancers10090293 · Cited by 60
Induction of lipid metabolism dysfunction, oxidative stress and inflammation response by tris(1-chloro-2-propyl)phosphate in larval/adult zebrafish
Yan, J., Zhao, Z., Xia, M., Chen, S., Wan, X., He, A., Sheng, G. D., Wang, X., Qian, Q., & Wang, H. (2022) · Environment International · doi:10.1016/j.envint.2022.107081 · Cited by 52
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease
Donati, B., Pietrelli, A., Pingitore, P., Dongiovanni, P., Caddeo, A. M., Walker, L., Baselli, G., Pelusi, S., Rosso, C., Vanni, E., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1078 · Cited by 55
Self-citation
Differential Roles of Cysteinyl Cathepsins in TGF-β Signaling and Tissue Fibrosis
Zhang, X., Zhou, Y., Yu, X., Huang, Q. M., Fang, W., Li, J., Bonventre, J. V., Sukhova, G. K., Libby, P., & Shi, G. (2019) · iScience · doi:10.1016/j.isci.2019.08.014 · Cited by 51
TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis
Aizawa, S., Okamoto, T., Sugiyama, Y., Kouwaki, T., Ito, A., Suzuki, T., Ono, C., Fukuhara, T., Yamamoto, M., Okochi, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11379 · Cited by 49
Obesity and Liver Cancer
Aleksandrova, K., Stelmach-Mardas, M., & Schlesinger, S. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42542-9_10 · Cited by 52
The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
Dongiovanni, P., Rametta, R., Meroni, M., & Valenti, L. V. C. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1110018 · Cited by 48
Self-citation
Influence of ethnicity on the distribution of genetic polymorphisms associated with risk of chronic liver disease in South American populations
Pontoriero, A., Trinks, J., Hulaniuk, M. L., Caputo, M., Fortuny, L., Pratx, L. D. B., Frías, A., Torres, O. W., Nuñez, F., Gadano, A. C., et al. (2015) · BMC Genetics · doi:10.1186/s12863-015-0255-3 · Cited by 42
Protective effect of ursodeoxycholic acid, resveratrol, and N -acetylcysteine on nonalcoholic fatty liver disease in rats
Ali, M. H. H., Messiha, B. A. S., & Abdellatif, H. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1060247 · Cited by 38
Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights
Sanchez, P. B. M., Krizanac, M., Weiskirchen, R., & Asimakopoulos, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105284 · Cited by 36
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Jeong, S., Oh, Y. H., Ahn, J. C., Choi, S., Park, S. J., Kim, H. J., Lee, G., Son, J. S., Jang, H., Lee, D. H., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0145 · Cited by 37
Anti-fibrotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fibrosis in rats
Li, D., Li, W., Chen, Y., Liu, L., Ma, D., Wang, H., Zhang, L., Zhao, S., & Qin, P. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy024 · Cited by 36
Sphingolipids at the Crossroads of NAFLD and Senescence
Nikolova‐Karakashian, M. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.05.002 · Cited by 35
PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
Lombardi, R., Piciotti, R., Dongiovanni, P., Meroni, M., Fargion, S., & Fracanzani, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052707 · Cited by 28
Self-citation
Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature.
Chin, K. M., Prieto, M., Cheong, C., di Martino, M., Ielpo, B., Goh, B., & Koh, Y. (2021) · HPB · doi:10.1016/j.hpb.2021.01.009 · Cited by 30
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
Panera, N., Meroni, M., Longo, M., Crudele, A., Valenti, L. V. C., Bellacchio, E., Miele, L., Doria, V., Paolini, E., Maggioni, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103249 · Cited by 31
Self-citation
Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey
Cotrim, H. P., de Oliveira, C. P. M. S., Coelho, H. S., Álvares‐da‐Silva, M. R., Nabuco, L. C., Parise, E. R., Ivantes, C. A. P., Martinelli, A. L. C., Filho, J. G., & Carrilho, F. J. (2016) · Clinics · doi:10.6061/clinics/2016(05)07 · Cited by 31
Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes
Chavda, V. P., Zajac, K. K., Gunn, J., Balar, P. C., Khadela, A. D., Vaghela, D. A., Soni, S., Ashby, C. R., & Tiwari, A. K. (2023) · Cancer Reports · doi:10.1002/cnr2.1821 · Cited by 26
Epidemiology of Hepatocellular Carcinoma
Giunchi, F., Vasuri, F., & Fiorentino, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-35153-7_23 · Cited by 26
Cancer of the Liver and its Relationship with Diabetes mellitus
Onikanni, S. A., Lawal, B., Bakare, O. S., Ajiboye, B. O., Ojo, O. A., Farasani, A. M., Kabrah, S. M., Batiha, G. E., & Conte‐Júnior, C. A. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221119743 · Cited by 24
DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application
Longo, M., Paolini, E., Benedetto, P. D., Tomassini, E., Meroni, M., & Dongiovanni, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169074 · Cited by 23
Self-citation
MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression
Tian, Q., Xiao, Y., Wu, Y., Liu, Y., Song, Z., Gao, W., Zhang, J., Yang, J., Zhang, Y., Guo, T., et al. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2754 · Cited by 23
Retracted
Caring for children with NAFLD and navigating their care into adulthood
Mencin, A., Loomba, R. S., & Lavine, J. E. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.146 · Cited by 22
“Weighing the risk”: Obesity and outcomes following liver transplantation
Reichman, T. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i11.1484 · Cited by 22
Identifying High-Risk NASH Patients: What We Know so Far
Schulz, M., & Tacke, F. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265473 · Cited by 21
Downregulation of long non-coding RNA MEG3 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by upregulating TGF-β1
Dong, H. F., Zhang, Y., Xu, Y. H., Ma, R., Liu, L., Luo, C., & Jiang, W. (2019) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmz046 · Cited by 21
A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis
Ullah, A., Chen, G., Zhang, Y., Hussain, A., Shafiq, M., Raza, F., Liu, D., Wang, K., Cao, J., & Qi, X. (2022) · Biomaterials Science · doi:10.1039/d2bm00242f · Cited by 22
[Retracted] MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression
Tian, Q., Xiao, Y., Wu, Y., Liu, Y., Song, Z., Gao, W., Zhang, J., Yang, J., Zhang, Y., Guo, T., et al. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5003 · Cited by 20
Retracted
Extrahepatic Upregulation of Transforming Growth Factor Beta 2 in HCV Genotype 4-Induced Liver Fibrosis
El-Meguid, M. A., Dawood, R. M., Mokhles, M. A., & Awady, M. K. E. (2018) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0045 · Cited by 18
Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions
Li, M., Larsen, F. T., van den Heuvel, M. C., Gier, K., Gorter, A. R., Oosterhuis, D., Bijzet, J., de Meijer, V. E., Ravnskjær, K., Nagelkerke, A., et al. (2024) · Nutrients · doi:10.3390/nu16050626 · Cited by 18
Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults
Ogawa, Y., Yoneda, M., Kobayashi, T., Honda, Y., Kessoku, T., Imajo, K., Saito, S., & Nakajima, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1543403 · Cited by 18
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD
Dongiovanni, P., Meroni, M., Petta, S., Longo, M., Alisi, A., Soardo, G., Valenti, L. V. C., Miele, L., Grimaudo, S., Pennisi, G., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158765 · Cited by 19
Self-citation
Prevention of Lipid Peroxidation–derived Cyclic DNA Adduct and Mutation in High-Fat Diet–induced Hepatocarcinogenesis by Theaphenon E
Coia, H., Ma, N., Hou, Y., Dyba, M. D., Fu, Y., Cruz, M. I., Benitez, C., Graham, G. T., McCutcheon, J. N., Zheng, Y., et al. (2018) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-18-0160 · Cited by 16
Xanthophyll β‐Cryptoxanthin Inhibits Highly Refined Carbohydrate Diet–Promoted Hepatocellular Carcinoma Progression in Mice
Lim, J. Y., Liu, C., Hu, K., Smith, D. E., Wu, D., Lamon‐Fava, S., Ausman, L. M., & Wang, X. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900949 · Cited by 16
Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum
Tavaglione, F., Targher, G., Valenti, L. V. C., & Romeo, S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.179 · Cited by 15
Long-Term Outcomes of Nonalcoholic Fatty Liver Disease
Kwak, M., & Kim, D. (2015) · Current Hepatology Reports · doi:10.1007/s11901-015-0258-6 · Cited by 16
Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents
Sakai, H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.394 · Cited by 15
Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology
Arora, S. P., Liposits, G. I., Caird, S., Dunne, R. F., Moffat, G. T., Okonji, D. O., Rodriquenz, M. G., Dua, D., & Dotan, E. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.10.007 · Cited by 14
Telomerase reverse transcriptase promoter mutations in hepatocellular carcinogenesis
Ma, Z.-X., Yang, C., Li, M., & Tu, H. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2018.104 · Cited by 15
Oxoglaucine Suppresses Hepatic Fibrosis by Inhibiting TGFβ-Induced Smad2 Phosphorylation and ROS Generation
Azamov, B., Lee, K. M., Hur, J., Muradillaeva, S., Shim, W.-S., Lee, C., & Song, P. (2023) · Molecules · doi:10.3390/molecules28134971 · Cited by 13
Hedgehog signaling is a promising target for the treatment of hepatic fibrogenesis: a new management strategy using itraconazole-loaded nanoparticles
Elmorsy, E. A., Saber, S., Kira, A. Y., Alghasham, A., Abdel-Hamed, M. R., Amer, M. M., Mohamed, E. A. K., Ali, A., Alkhamiss, A. S., Hamad, R. S., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1377980 · Cited by 13
Association of Methylation Signatures at Hepatocellular Carcinoma Pathway Genes with Adiposity and Insulin Resistance Phenotypes
Ramos-López, O., Riezu‐Boj, J. I., Milagro, F. I., Martínez, J. A., & On Behalf of the MENA Project (2018) · Nutrition and Cancer · doi:10.1080/01635581.2018.1531136 · Cited by 13
Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation
Gu, J., Yao, M., Yao, D., Wang, L., Yang, X., & Yao, D. (2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2016.00010 · Cited by 13
Beneficial body mass index to enhance survival outcomes in patients with early-stage hepatocellular carcinoma following microwave ablation treatment
Dou, J., Han, Z., Liu, F., Cheng, Z., Yu, X., Yu, J., & Liang, P. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1712482 · Cited by 13
Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis – epidemiology, risk factors, clinical implications and treatment
Straś, W., Małkowski, P., & Tronina, O. (2020) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2020.99506 · Cited by 13
Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
Campani, C., Bensi, C., Milani, S., Galli, A., & Tarocchi, M. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s252506 · Cited by 12
The Spectrum of E2F in Liver Disease-Mediated Regulation in Biology and Cancer
Huntington, J. T., Tang, X., Kent, L. N., Schmidt, C. R., & Leone, G. W. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25242 · Cited by 12
Differential impacts of mineralocorticoid receptor antagonist potassium canrenoate on liver and renal changes in high fat diet-mediated early hepatocarcinogenesis model rats
Nakamura, M., Eguchi, A., Inohana, M., Nagahara, R., Murayama, H., Kawashima, M., Mizukami, S., Koyanagi, M., Hayashi, S.-M., Maronpot, R. R., et al. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.611 · Cited by 12
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Prevalence of Hepatocellular Carcinoma in Hepatitis B Population within Southeast Asia: A Systematic Review and Meta-Analysis of 39,050 Participants
Rabaan, A., Bello, K., Irekeola, A., Kaabi, N. A., Halwani, M. A., Yousuf, A., Alshengeti, A. M., Alfaraj, A. H., Khamis, F., Al-Subaie, M. F., et al. (2023) · Pathogens · doi:10.3390/pathogens12101220 · Cited by 13
Diagnostic value of imaging examinations in patients with primary hepatocellular carcinoma
Li, X., Liang, Q., Chen, T., Wang, J., & Zhang, X. M. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i9.242 · Cited by 11
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
Berardi, G., Cucchetti, A., Sposito, C., Ratti, F., Nebbia, M., D’souza, D., Pascual, F., Dogeas, E., Tohme, S., Vitale, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101075 · Cited by 14
Common Denominator of MASLD and Some Non-Communicable Diseases
Ferenc, K., Jarmakiewicz-Czaja, S., Sokal-Dembowska, A., Stasik, K., & Filip, R. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070399 · Cited by 9
Hedgehog components are overexpressed in a series of liver cancer cases
Sales, C. B. S., Dias, R. B., Valverde, L. D. F., Bomfim, L. M., Silva, L. A., de Carvalho, N. C., Bastos, J., Tilli, T. M., Rocha, G. V., Soares, M. B. P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70220-0 · Cited by 9
Possibilistics C-Means (PCM) Algorithm for the Hepatocellular Carcinoma (HCC) Classification
Khairi, R., Rustam, Z., & Utama, S. (2019) · IOP Conference Series Materials Science and Engineering · doi:10.1088/1757-899x/546/5/052038 · Cited by 9
Target identification of hepatic fibrosis using Pien Tze Huang based on mRNA and lncRNA
Zhu, J., Zhang, D., Wang, T., Chen, Z., Chen, L., Wu, H., Huai, C., Sun, J. P., Zhang, N., Wei, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96459-5 · Cited by 9
Hepatocellular carcinoma versus nonalcoholic fatty liver disease: metabolic, environmental, and genetic association? De facto?
Toman, D., Şengül, İ., Pelikán, A., Şengül, D., Vavra, P., Ihnat, P. M., Roman, J., & Kayaalp, C. (2022) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220147 · Cited by 8
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma
Cammarota, A., D’Alessio, A., Pressiani, T., Rimassa, L., & Personeni, N. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00871-5 · Cited by 7
Evolution of Non-alcoholic Fatty Liver Disease to Liver Cancer: Insights from Genome-wide Association Studies
Mungamuri, S. K., Gupta, Y. K., Rao, P. N., & Ravishankar, B. (2023) · Gene Expression · doi:10.14218/ge.2022.00014 · Cited by 6
Újabb adatok a nem alkoholos zsírmáj patogeneziséhez
Pár, A., & Pár, G. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30775 · Cited by 11
Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Modern Context for an Ancient Disease
Gallo, P., Silletta, M., Prinzi, F. L., Farolfi, T., & Coppola, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144605 · Cited by 6
Obesity and Hepatocellular Carcinoma
Xu, W., & Yu, J. Q. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804274-8.00020-5 · Cited by 6
Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
Meroni, M., Longo, M., & Dongiovanni, P. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00015 · Cited by 5
Self-citation
MicroRNA301 is a potential diagnostic biomarker for hepatocellular cancer.
He, K., Hu, Z., Ruan, J., Ma, Q., Zhong, F., Cheng, X., Sun, S., & Zhou, J. (2015) · PubMed Central · Cited by 5

Authors: Dongiovanni, P.
Affiliations: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Corresponding author: Dongiovanni, Paola
ORCID: Dongiovanni, Paola
Venue: World Journal of Gastroenterology
Publisher: Baishideng Publishing Group Inc.
Published: 2014
Volume: 20
Issue: 36
Pages: 12945
ISSN: 1007-9327 (ISSN-L)
DOI: 10.3748/wjg.v20.i36.12945
PMC: PMC4177475
OpenAlex: W2018207417
Cited by: 145
References: 124
Citations by year: 2026: 6 · 2025: 5 · 2024: 11 · 2023: 7 · 2022: 11 · 2021: 13 · 2020: 16 · 2019: 12 · 2018: 19 · 2017: 12 · 2016: 17 · 2015: 16
FWCI: 2.00
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: World Journal of Gastroenterology (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Novo Nordisk Fonden (NNF14OC0009321)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: hepatocellular carcinoma, non-alcoholic fatty liver disease, insulin resistance, PNPLA3 I148M variant, telomerase reverse transcriptase, cellular senescence, gut microbiota, obesity, type 2 diabetes, iron overload, hepatocarcinogenesis, genetic susceptibility, environmental risk factors
MeSH terms: Animals, Carcinoma, Hepatocellular, Humans, Liver, Liver Neoplasms, Phenotype, Prognosis, Risk Factors, Disease Progression, Risk Assessment, Genetic Predisposition to Disease, Gene-Environment Interaction, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks